WuXi AppTec Co., Ltd.

WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, rest of Asia, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.

WuXi STA, a subsidiary of WuXi AppTec

WuXi Discovery Services

Medical Device Testing

Laboratory Testing Division, Drug Discovery and Development

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the pharmaceutical and healthcare industry around the world to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, and cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received AA ESG rating from MSCI in 2022 and its open-access platform is enabling more than 5,950 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."

UNITY Biotechnology

JW Therapeutics

Rodeo Therapeutics

CANbridge Pharmaceuticals

Schrödinger

Hua Medicine

Immunocore

Ping An Bank

Warburg Pincus

Eight Roads Ventures

Commerce Health Capital

NewSpring

WuXi AppTec

🙌 A big thank you to all who joined us yesterday for our digital #WuXiGlobalForum!

In case you missed it, subscribe to our newsletter for insights into our BOLD online series, highlighting influential global thought leaders #TakingBOLDAction in the healthcare industry by:
✅ Breaking Barriers
✅ Opening New Horizons
✅ Leading Next Generation
✅ Delivering for Patients

Signup here: https://lnkd.in/gsYmcC9u

Exciting progress! WuXi STA, a subsidiary of WuXi AppTec announced the launch of its new Blow-Fill-Seal (#BFS) aseptic filling line at the Wuxi City site! This expansion aligns with our continuous efforts to strengthen #CRDMO platform capabilities, empowering our global partners to accelerate more innovative therapies for patients worldwide.

Stay tuned for more updates! #Innovation #Healthcare

🎥 Tune in on WEDNESDAY at 7 AM or 7 PM PST to see prominent industry experts cover our industry's progress and the path toward catalyzing change for patients.

Don't miss out on the digital #WuXiGlobalForum! https://lnkd.in/geY5pHqp

Get ready, #WuXiGlobalForum 2024’s online premiere is just around the corner! 

Join us on January 31st as we bring together distinguished innovators and leading VCs to cover the industry’s next big breakthroughs for global patients, essentials of establishing cutting-edge platforms, and how to integrate them into the future of medicine:
✅ Leading Transformation: The Next Wave Therapeutics
✅ Delivering on Future Platform Solutions
✅ Scaling Breakthroughs Forward
 
Esteemed panelists include Vineeta Agarwala, Alexis Borisy, Wolfram Carius, John Carroll, Abraham (Abe) Ceesay, Pavan Cheruvu, Giuseppe Ciaramella, Miles Congreve, Evan Feinberg, Kevin Forrest, Laura Furmanski, Edward Hu, Ann Lee-Karlon, Nevan Krogan, Rogier Rooswinkel, Amber Salzman, Tim Shannon, John Wesley, Sabrina Yang, and Steve Yang.
 
🎟️ Reserve your complimentary ticket, airing twice at 7 AM & 7 PM PST: 
https://lnkd.in/geY5pHqp

As an integrated #testing platform across the full life cycle of discovery and development, WuXi Testing, one of the key business segments of WuXi AppTec, provides "end-to-end" testing services for novel drug developers and medical device manufacturers. With our wide-ranging expertise, we help our customers at every developmental stage, advancing their endeavors to bring life-saving products to patients in need.
 
Ready to see innovation in action? Watch the video for an exclusive one-minute glimpse into our meaningful work!
 
#DMPK #Bioanalytical #SafetyAssessment #ClinicalTrials #Innovation

What are some of our proud moments in 2023 despite a challenging year? How do we continue fostering innovation in 2024? What’s the next major leap forward? 
 
Join the conversation on January 31st as we uncover the future of healthcare innovation and hear from our distinguished experts: 
✅ State of Innovation 2024
✅ Breaking Barriers. Leaping Forward.
✅ Opening Up New Horizons: Spotlight on Cancer

Featuring: Amy Abernethy, Robert Gabbay, Margo Georgiadis, Donald Ingber, Philip Kantoff, Samir Khleif, Karen Knudsen, Crystal Mackall, Mathai Mammen, John Maraganore, Søren Møller, Briggs Morrison, Karen Tkach Tuzman, Christoph Westphal, and Joseph C. Wu
 
🔍 Register for the digital #WuXiGlobalForum today! https://lnkd.in/geY5pHqp

Two weeks ago, thousands gathered at our 12th WuXi Global Forum during #JPM24 to catalyze new thinking on advancing breakthroughs for patients. With overwhelming community interest, we’re delighted to unveil the digital premiere of #WuXiGlobalForum 2024, complimentary and open to the global innovation ecosystem. Mark your calendars to participate in the discussions!

📅 Date: January 31, 2024 
⏰ Times: 7am & 7pm PST
 
Register now: https://lnkd.in/geY5pHqp

Approval News: Congratulations! #Voydeya (#danicopan) was approved in Japan for adults with paroxysmal nocturnal haemoglobinuria (#PNH) to be used in combination with C5 inhibitor therapy.

PNH is a rare and severe blood disorder characterized by the destruction of red blood cells within blood vessels, and white blood cell and platelet activation that can cause thrombosis (blood clots) and result in organ damage and potentially premature death. Voydeya, as add-on to standard-of-care, has the potential to improve outcomes for those experiencing the burdensome manifestations of extravascular haemolysis while continuing treatment with standard of care.

🎉 Read more here: https://bit.ly/3O9h9pQ

AstraZeneca #RareDisease #healthcare #medicine #biotechnology #pharma

Discover WuXi STA, a subsidiary of WuXi AppTec’s thriving #SanDiego site! Nestled in Sorrento Valley, a renowned biotech hub, this cutting-edge facility offers top-tier services in process R&D and GMP manufacturing for small molecule API and drug products. 

With a team of experts, the site is dedicated to providing integrated services to global customers and enabling their life-saving work for patients in need.
#healthcare #innovation

Thank you to the thousands of friends and colleagues who joined us on Tuesday for our annual #WuXiGlobalForum at #JPM2024. We’re immensely grateful to our distinguished panelists who shared their remarkable insights and expertise. 

As a convener within the global healthcare community, we are truly inspired by the collaboration, innovative thinking, and wisdom shared. 
 
#TakingBOLDAction will lead to real change for patients and families around the world.

6032

HKSE:2359

WuXi AppTec

Last Close

38.71

30/08 07:00

Market Cap

107.59B

Beta: 0.75

Volume Today

41.06M

Avg: 2.09M

PE Ratio

12.92

PFCF: 36.92

Dividend Yield

2.37%

Payout:29.01%

Analysis Not Available